SCHEMBL4053418

SCHEMBL4053418

CCOCCOc1ccc(C(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.46
MAOB P27338 2/20 0.46
THRA P10827 1/20 0.45
ACACB O00763 1/20 0.45
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NCF1 P14598 2/20 0.44
KDM4E B2RXH2 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
NQO1 P15559 1/20 0.43
MMP3 P08254 1/20 0.42
SLC2A1 P11166 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15275326 0.98 L3MBTL1 (0.49) MEN1KMT2AL3MBTL1MAOBTHRA
SCHEMBL21306263 0.91 MEN1 (0.53) MEN1KMT2AMAOBLMNAHTT
SCHEMBL10824702 0.88 KMT2A (0.59) MEN1KMT2AMAOBLMNAHTT
SCHEMBL4061378 0.85 NQO1 (0.57) MEN1KMT2AL3MBTL1THRAACACB
SCHEMBL23236719 0.84 NQO1 (0.46) MEN1KMT2AL3MBTL1LMNAHTT
SCHEMBL19928222 0.84 ALDH1A1 (0.55) MEN1KMT2AL3MBTL1THRAACACB
SCHEMBL9150174 0.83 KDM4E (0.56) MEN1KMT2AL3MBTL1THRALMNA
SCHEMBL15701618 0.83 NCF1 (0.54) MAOBSMN1; SMN2NCF1KDM4ETDP1
SCHEMBL13981330 0.83 KDM4E (0.50) MEN1KMT2AL3MBTL1MAOBLMNA
SCHEMBL18127062 0.83 KDM4E (0.50) MEN1KMT2AL3MBTL1MAOBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022120207-A1 BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX UNIVERSITY OF MARYLAND, BALTIMORE (US) 2022-06-09 WO disclosed
US-7534547-B2 Optically active compound and photosensitive resin composition OSAKA GAS COMPANY LIMITED (JP) 2009-05-19 US disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US disclosed
US-20080032975-A1 Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2008-02-07 US disclosed
US-7282498-B2 Substituted fused pyrroleoximes and fused pyrazoleoximes NEUROGEN CORPORATION (US) 2007-10-16 US disclosed
EP-1375463-A1 OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION Kansai Research Institute, Inc. (JP) 2004-01-02 EP disclosed
US-20030211421-A1 Optically active compound and photosensitive resin composition KRI, INC. (JP) 2003-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032975-A1 Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes NPSR1, GABRE, CHRNE MEN1 3929/4885KMT2A 1103/4885L3MBTL1 2831/4885
US-20030211421-A1 Optically active compound and photosensitive resin composition ARCN1, RAD51, PAM MEN1 754/4885KMT2A 1062/4885L3MBTL1 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.